Avecho Biotechnology Limited
AVEFF
$0.0045
-$0.0129-74.14%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 267.30K | 274.90K | 102.90K | 102.70K | 8.80K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 267.30K | 274.90K | 102.90K | 102.70K | 8.80K |
| Cost of Revenue | 115.90K | 119.20K | 34.60K | 34.50K | 126.80K |
| Gross Profit | 151.40K | 155.70K | 68.30K | 68.10K | -117.90K |
| SG&A Expenses | 287.60K | 295.70K | 381.20K | 380.40K | 227.50K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 559.00K | 574.80K | 817.70K | 816.10K | 432.90K |
| Operating Income | -291.70K | -299.90K | -714.90K | -713.40K | -424.00K |
| Income Before Tax | -308.50K | -317.20K | -716.70K | -715.30K | -426.60K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -308.50K | -317.20K | -716.70K | -715.30K | -426.60K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -308.50K | -317.20K | -716.70K | -715.30K | -426.60K |
| EBIT | -291.70K | -299.90K | -714.90K | -713.40K | -424.00K |
| EBITDA | -268.80K | -276.40K | -690.30K | -688.90K | -399.80K |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 3.17B | 3.17B | 3.17B | 3.17B | 2.61B |
| Average Diluted Shares Outstanding | 3.17B | 3.17B | 3.17B | 3.17B | 2.61B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |